Drug Repurposing Market Size & Share 2026 - 2034

Drug Repurposing Market Size

The global drug repurposing market was valued at USD 33.8 billion in 2025. The market is expected to grow from USD 35.1 billion in 2026 to USD 51.1 billion in 2034, at a CAGR of 4.8% during the forecast period according to the latest report published by Global Market Insights Inc.

The Drug Repurposing Market is expanding rapidly as pharmaceutical companies increasingly use approved and investigational drugs to address high-burden diseases such as cancer, Alzheimer's disease, chronic kidney disease, rare genetic disorders, and neurological conditions. Drug repurposing, also known as drug repositioning, enables researchers to identify new therapeutic indications for existing molecules with established safety and pharmacological profiles, significantly reducing development risk, cost, and commercialization timelines.

Unlike traditional drug discovery, which can take more than a decade and require investments exceeding USD 2 billion, repurposed drugs often bypass early-stage safety studies, allowing companies to accelerate clinical development and regulatory approvals while improving return on investment. The growing number of successful label expansions—including cariprazine for major depressive disorder and empagliflozin for chronic kidney disease—highlights the increasing adoption of this strategy to meet unmet clinical needs and improve patient access to innovative therapies.

Advances in artificial intelligence (AI), machine learning, bioinformatics, real-world evidence, and genomics are further transforming the drug repurposing landscape by helping researchers identify promising drug-disease relationships with greater speed and precision. As healthcare systems seek cost-effective therapeutic solutions and pharmaceutical companies focus on maximizing the value of existing drug portfolios, demand for drug repurposing continues to strengthen across both developed and emerging markets.

Leading participants, including Recursion Pharmaceuticals, Pfizer, Novartis, Eli Lilly and Company, and Melior Discovery, are expanding their competitive position through AI-driven discovery platforms, strategic collaborations, portfolio expansion, and global commercialization initiatives, reinforcing the market's long-term growth potential.

Drug Repurposing Market Trends

• The market is witnessing strong growth as pharmaceutical companies seek faster, lower-risk, and cost-effective alternatives to traditional drug development. With thousands of diseases, including rare diseases and chronic conditions, still lacking approved therapies, drug repurposing enables existing approved or investigational drugs to be evaluated for new therapeutic indications, significantly reducing development timelines and clinical costs. Artificial intelligence (AI), machine learning, real-world evidence (RWE), genomics, and advanced data analytics are transforming drug repurposing strategies by accelerating target identification, predicting drug-disease relationships, and improving clinical success rates.
• Oncology, central nervous system (CNS) disorders, infectious diseases, and rare diseases remain the leading application areas, while small molecules continue to dominate due to established safety profiles, although biologics and combination therapies are gaining momentum with advances in precision medicine. Increasing collaborations among pharmaceutical companies, biotechnology firms, academic research organizations, contract research organizations (CROs), and technology providers are expanding innovation, with AI-driven partnerships such as Every Cure and
• Google Cloud highlighting the industry's digital transformation. Regulatory agencies, including the FDA and EMA, are also supporting the use of real-world evidence and adaptive approval pathways, making repurposed drugs more viable for underserved patient populations. In parallel, new commercialization models, public-private partnerships, and lifecycle management strategies are addressing intellectual property challenges associated with repurposed medicines.
• North America continues to lead the market due to its advanced research ecosystem, favorable regulatory environment, and strong investment activity, while Asia Pacific is expected to record the fastest growth, supported by expanding clinical trial infrastructure, lower research costs, rising healthcare investments, and increasing pharmaceutical R&D across emerging economies. 

Drug Repurposing Market Analysis

Based on drug type, the drug repurposing market is divided into small molecules and biologics. The small molecules segment accounted for 67.4% of the market in 2025. The segment is expected to exceed USD 33.8 billion by 2034, growing at a CAGR of 4.6% during the forecast period.
 

• Small molecules have well-documented pharmacokinetics, safety profiles, and manufacturing processes, making them ideal candidates for repurposing. Their prior approval allows developers to leverage existing clinical data, reducing the need for extensive trials. Regulatory frameworks like the FDA’s 505(b)(2) pathway enable faster approvals by referencing prior data, significantly cutting time and cost.
   
• Small molecules are easier and cheaper to synthesize compared to biologics. Their chemical stability and simpler production processes allow for large-scale manufacturing using existing infrastructure. This cost-efficiency is crucial for repurposing, where rapid deployment is often needed.
   
• Additionally, their compatibility with combination therapies and potential for oral administration enhances patient compliance and market adoption. This broad applicability supports continuous innovation and expansion of repurposing pipelines.
   
• The biologics segment of the drug repurposing market is projected to grow significantly with a CAGR of 5.1%. Biologics, including monoclonal antibodies, recombinant proteins, and gene therapy, offer high specificity and efficacy in targeting disease mechanisms. This makes them ideal for repurposing         g in complex conditions like cancer, autoimmune disorders, and neurological diseases.
   
• Moreover, their ability to interact with specific cellular pathways allows for precision treatment, reducing off-target effects. For instance, biologics such as Leqembi (lecanemab) have been repurposed for Alzheimer’s disease, showing promising results in slowing cognitive decline.
   
• Thus, as biologics continue to demonstrate superior therapeutic outcomes, their repurposing potential grows, especially in areas with unmet medical needs.
   

Based on the therapeutic area, the drug repurposing market is segmented into oncology, neurology and CNS disorders, infectious diseases, cardiovascular diseases, metabolic disorders, and other therapeutic areas. The oncology segment dominated the market in 2025 with a revenue of USD 12.8 billion.
 

• The increasing prevalence of cancer worldwide is a major driver for oncology-focused drug repurposing. According to the American Cancer Society, over 2 million new cancer cases were reported in the U.S. alone in 2024. This surge in diagnoses across all age groups has intensified the demand for effective and affordable treatments.
   
• Drug repurposing offers a faster route to address this need by utilizing existing drugs with known safety profiles. It enables quicker access to therapies, especially for aggressive cancers such as lung, breast, and colorectal, where time-sensitive intervention is critical. This urgency is pushing pharmaceutical companies to explore repurposing as a strategic solution, thereby driving the growth of the market.
   
• In addition, government initiatives and public-private partnerships are fueling oncology drug repurposing. For instance, Every Cure received a USD 48.3 million federal contract from ARPA-H in 2024 to support repurposing efforts for cancer and other diseases.
   
• These incentives, combined with rising healthcare expenditures and global awareness campaigns, are encouraging pharmaceutical companies to invest in repurposing strategies that further contribute to market growth.
   
• The neurology and CNS disorders segment of the drug repurposing market is projected to grow significantly during the analysis period owing to increasing global burden of neurological and psychiatric conditions such as Alzheimer’s, Parkinson’s, epilepsy, depression, and schizophrenia.
   
• Additionally, growing focus on mental health and societal awareness leads to increasing diagnosis and demand for effective treatments for conditions such as depression, anxiety, bipolar disorder, and schizophrenia. This societal shift is influencing healthcare policies, insurance coverage, and pharmaceutical priorities thereby boosting market growth.
   

Based on route of administration, the drug repurposing market is classified into oral, intravenous, and other routes of administration. The oral segment dominated the market in 2025 with USD 19 billion.
 

• Oral drugs are widely applicable across multiple therapeutic areas, including oncology, CNS disorders, infectious diseases, and metabolic conditions. Their ability to deliver systemic effects makes them suitable for treating both acute and chronic illnesses.
   
• In drug repurposing, oral formulations are often prioritized due to their versatility and established pharmacokinetic profiles. For example, many antiviral and anticancer agents originally developed for one indication have been successfully repurposed for others using oral delivery. This broad applicability enhances the commercial viability of repurposed oral drugs and supports their continued dominance in the market.
   
• The intravenous segment grew with a CAGR of 5.1% during the analysis period. Biologics, including monoclonal antibodies and recombinant proteins, are often administered intravenously due to their molecular complexity and sensitivity to digestion.
   
• The widespread availability of hospital infrastructure for IV drug administration supports the growth of this segment. Clinical trials for repurposed drugs often begin in controlled environments, and IV delivery is preferred for its dosing accuracy and monitoring capabilities.

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, drug repurposing market is classified into pharmaceutical and biotechnology companies, contract research organization (CROs) and other end users. The pharmaceutical and biotechnology companies segment dominated the market in 2025 and is expected to reach USD 25.1 billion by 2034.
 

• Pharmaceutical and biotech companies are increasingly turning to drug repurposing to reduce the high costs and risks associated with traditional drug development. Repurposing allows them to leverage existing compounds with known safety profiles, significantly cutting down on preclinical and early-stage trial expenses.
   
• Pharmaceutical and biotech companies are increasingly adopting AI, machine learning, and big data analytics to identify new indications for existing drugs. These technologies enable faster target identification, lead optimization, and clinical trial design, boosting market share for this segment.
   
• Drug repurposing enables pharmaceutical and biotech companies to stay competitive by rapidly responding to emerging health threats and unmet medical needs. The ability to bring therapies to market faster than traditional research and development gives companies a strategic edge. For example, during the COVID-19 pandemic, repurposed drugs like remdesivir and dexamethasone were deployed quickly, demonstrating the value of this approach.

North America Drug Repurposing Market
 

The North America market dominated the market with a market share of 48.2% in 2025.
 

• North America, particularly the U.S., benefits from a well-established regulatory infrastructure that supports drug repurposing. The FDA’s 505(b)(2) pathway allows companies to use existing safety and efficacy data to gain approval for new indications, significantly reducing development time and cost. This regulatory flexibility encourages pharmaceutical and biotech firms to invest in repurposing strategies.
   
• North America has significant public and private investment in drug repurposing research. The National Institutes of Health (NIH) allocated USD 1.15 billion through the RECOVER initiative in 2021.
   
• Additionally, the NIH's National Center for Advancing Translational Sciences (NCATS) dedicated USD 8.2 million in 2022 specifically for drug repurposing research. The funding is projected to reach USD 2.5 billion by 2025, particularly focusing on responses to public health emergencies.
   

The U.S. drug repurposing market size reached USD 14.6 billion in 2025. 

• The U.S. maintains one of the highest healthcare expenditures globally, accounting for 18.3% of GDP in 2021, according to the Centers for Medicare and Medicaid Services (CMS). National health spending is projected to reach USD 6.2 trillion by 2025. Drug repurposing reduces research and development costs while accelerating time-to-market, with the FDA reporting a 60% reduction in development timelines for repurposed drugs between 2021-2023.
   
• This approach is especially beneficial for managing chronic conditions such as diabetes, cancer, and cardiovascular diseases, which require extended treatment periods and collectively account for 75% of the nation's annual healthcare costs, as reported by the CDC in 2023.
   
• The U.S. is home to a robust research ecosystem comprising leading pharmaceutical companies, biotech startups, academic institutions, and government agencies. Collaborations between these entities are fueling innovation in drug repurposing.
   

Europe Drug Repurposing Market
 

Europe market accounted for USD 8.54 billion in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• The European Medicines Agency (EMA) has introduced adaptive licensing and other flexible regulatory pathways that support drug repurposing. These frameworks allow companies to use existing safety and efficacy data to gain approval for new indications, reducing the need for full clinical trials. This is particularly beneficial for rare diseases and urgent therapeutic needs.
   
• The EMA also encourages real-world evidence and post-marketing surveillance, which helps validate repurposed drugs in broader populations. These regulatory incentives make Europe a favorable region for pharmaceutical and biotech firms to pursue repurposing strategies.
   
• Europe has a robust network of academic institutions, public health agencies, and research organizations actively involved in drug repurposing. These entities collaborate with pharmaceutical companies and biotech firms to identify new uses for existing drugs. EU-funded programs and Horizon Europe initiatives support cross-border research and innovation in drug repurposing.
   

Germany dominates the European drug repurposing market, showcasing strong growth potential.
 

• Germany is home to leading pharmaceutical and biotech companies such as Bayer, Merck KGaA, and Boehringer Ingelheim, which possess extensive drug portfolios and research and development capabilities. These firms are actively exploring repurposing opportunities to extend product lifecycles and enter new therapeutic areas. The country’s industrial strength supports innovation through advanced manufacturing, regulatory expertise, and global distribution networks, driving market growth.
   
• Germany's research infrastructure includes institutions such as the Max Planck Society, Fraunhofer Institutes, and universities. According to the Federal Ministry of Education and Research (BMBF), Germany invested EUR 104.7 billion in research and development in 2021, with 15% allocated to pharmaceutical research.
   
• The German government's 2025 Research and Innovation strategy aims to increase research and development spending to 3.5% of GDP, with EUR 25 billion specifically dedicated to drug development and repurposing initiatives. The partnerships between academic institutions and pharmaceutical companies support early-stage discovery and validation, which reduces the risks associated with drug repurposing projects. The German Research Foundation (DFG) reported funding 387 drug repurposing projects between 2021-2023, with a success rate of 42% in identifying viable new applications.
   

Asia Pacific Drug Repurposing Market
 

The Asia Pacific market is anticipated to grow at the highest CAGR of 5.1% during the analysis timeframe.
 

• Governments across Asia Pacific are implementing supportive policies and reforms to encourage pharmaceutical innovation, including drug repurposing. For example, China has streamlined its drug approval process, while Japan offers subsidies to boost local production. The region’s evolving regulatory landscape is creating a more favorable environment for faster approvals and commercialization of repurposed drugs.
   
• Asia Pacific has established itself as a global pharmaceutical manufacturing hub, with India and China dominating generic drug production. According to the Indian Ministry of Commerce and Industry, India's pharmaceutical exports reached USD 24.6 billion in FY 2021-22, with generic drugs accounting for 70% of the total exports.
   
• In addition, China's National Medical Products Administration reported that the country's pharmaceutical manufacturing output value reached CNY 3.4 trillion (USD 534 billion) in 2021. This manufacturing capacity allows quick deployment of repurposed therapies, particularly during health emergencies or drug shortages, contributing to market growth.
   

China drug repurposing market is estimated to grow with a significant CAGR, in the Asia Pacific market.
 

• The Chinese government has actively promoted drug repurposing as part of its broader healthcare reform strategy. Policies encouraging innovation, faster access to essential medicines, and improved patient outcomes have created a favorable environment for repurposing efforts. Funding programs and regulatory incentives are being introduced to support pharmaceutical research and development, especially for rare and chronic diseases.
   
• Collaborations between pharmaceutical companies and academic institutions in China are accelerating drug repurposing efforts. Universities and research centers contribute to early-stage discovery, while industry partners handle clinical development and commercialization. These partnerships are supported by government grants and innovation hubs, fostering a collaborative ecosystem for repurposing research.
   

Latin American Drug Repurposing Market
 

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.
 

• Brazil’s pharmaceutical sector is increasingly adopting drug repurposing as a cost-effective alternative to traditional drug discovery. Developing new drugs from scratch is expensive and time-consuming, often taking over a decade and billions in investment.
   
• Repurposing allows Brazilian companies to bypass early-stage trials by leveraging existing safety and efficacy data, significantly reducing research and development costs. This is particularly beneficial in Brazil’s public healthcare system (SUS), which seeks affordable treatment options for widespread diseases. As healthcare budgets tighten, repurposing offers a strategic solution to deliver effective therapies faster and at lower costs.
   
• Brazil faces a growing prevalence of chronic conditions such as cancer, cardiovascular diseases, and diabetes, alongside persistent infectious diseases like dengue and Zika. These health challenges often lack effective treatments, making drug repurposing a valuable strategy.
   

Middle East and Africa Drug Repurposing Market
 

Saudi Arabia market to experience substantial growth in the Middle East and Africa market in 2025.
 

• Saudi Arabia is rapidly building its pharmaceutical manufacturing capabilities, supported by local firms like SPIMACO and Tabuk Pharmaceuticals. These companies are investing in proprietary formulations and repurposing pipelines to move up the value chain.
   
• The development of research-driven pharmaceutical zones and innovation hubs is enhancing the country’s capacity for drug discovery and repurposing. This infrastructure growth supports faster production, clinical validation, and commercialization of repurposed drugs, reducing reliance on imports and improving supply chain resilience.
   
• With rising healthcare costs and a growing population, Saudi Arabia is prioritizing cost-effective treatment options. Drug repurposing offers a faster and more economical route to bring therapies to market, especially for diseases with limited treatment options. Hospitals and healthcare providers are increasingly adopting repurposed drugs to manage patient loads efficiently.
   

Drug Repurposing Market Share

The market is characterized by a dynamic and moderately fragmented competitive environment. Leading pharmaceutical and biotech companies are actively shaping the market through strategic investments in research and development, expansion into emerging regions, and the creation of patient-centric therapies targeting complex conditions such as cancer, autoimmune disorders, and infectious diseases. The key players of the market such as Recursion Pharmaceuticals, Pfizer, Novartis, Eli Lilly and Company, and Melior Discovery commanding a combined approximately 35% of global market share.
 

To strengthen their market positions, these companies are employing multi-faceted strategies including mergers and acquisitions, strategic alliances, and innovative pricing models. These efforts aim to enhance access to advanced therapies, improve affordability, and address unmet medical needs across diverse populations.
 

Simultaneously, emerging biotech firms and technology-driven startups are contributing to market evolution by introducing novel drug delivery systems such as subcutaneous formulations leveraging artificial intelligence for drug discovery. Their influence is particularly strong in regions like Asia-Pacific, Latin America, and the Middle East, where growing healthcare infrastructure and rising prevalence of chronic and rare genetic diseases are accelerating adoption.
 

As competition intensifies and therapeutic approaches diversify, companies are evolving their portfolios to meet global demand for effective, scalable, and personalized solutions. This ongoing innovation is fueling sustained growth and transforming the landscape of drug repurposing worldwide.
 

Drug Repurposing Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are onto clinical phase development. Prominent players operating in the market are as mentioned below:
 

• AbbVie
• Amgen
• Boehringer Ingelheim
• Cyclica
• Eli Lilly and Company
• GlaxoSmithKline
• Melior Discovery
• Novartis
• Pfizer
• Pharnext
• Recursion Pharmaceuticals
• Revolution Medicines
• Sanofi
• Schwarz Pharma
• Valence Discovery
   
• Recursion Pharmaceuticals

Recursion Pharmaceuticals leads the drug repurposing market with a share of ~12.5% in 2024. Recursion partnerships with Bayer and Roche validate its platform’s scalability. Its pipeline includes promising candidates like REC-617 (CDK7 inhibitor) and REC-4881 (MEK1/2 inhibitor), positioning it as a leader in precision repurposing for oncology and rare diseases.
 

• Pfizer

Pfizer’s patient-centric marketing, robust pipeline, and commitment to affordability through cost leadership and differentiated therapies make it a dominant force in both developed and emerging markets.
 

• Novartis  

The company’s global footprint, strong financials, and commitment to equitable healthcare access support its repurposing initiatives. Novartis also invests heavily in digital health and sustainability, reinforcing its competitive edge in scalable, patient-focused drug development across multiple therapeutic areas.

Drug Repurposing Market Industry News

• In July 2025, Biogen announced a USD 2 billion investment to expand its manufacturing facilities in Research Triangle Park, North Carolina. The expansion is intended to support production of innovative therapies, including biologics that may enable broader lifecycle management and new therapeutic indications. 
• In June 2026, GSK announced the acquisition of Nuvalent for USD 10.6 billion in cash. The transaction strengthens GSK's oncology pipeline with late-stage targeted therapies expected to generate up to USD 4 billion in peak annual sales, reinforcing the company's strategy to expand innovative treatment options. 
• In July 2025, Glenmark's innovation arm Ichnos Glenmark Innovation (IGI) signed an exclusive licensing agreement with AbbVie for the multiple myeloma drug ISB 2001. The agreement included an upfront payment of USD 700 million and potential milestone payments of up to USD 1.225 billion, highlighting growing investment in innovative drug development and repurposing approaches. 

The drug repurposing market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Small molecules
• Biologics         

Market, By Therapeutic Area

• Oncology
• Neurology and CNS disorders
• Infectious diseases
• Cardiovascular diseases
• Metabolic disorders
• Other therapeutic areas

Market, By Route of Administration

• Oral
• Intravenous
• Other routes of administration

Market, By End Use

• Pharmaceutical and biopharmaceutical companies
• Contract Research Organization (CROs)
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE